HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

NEW YORK – First Ascent Biomedical on Monday announced that it has received a $6 million investment from Vidal Duart Enterprises, as well as an additional co-investment from Techstars, which it will ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.